Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
The U.S. Food and Drug Administration approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents.
